非手术治疗原发性肝癌研究进展

doi:10.3969/j.issn.1672-5069.2016.02.037

摘要/Abstract

摘要： 肝细胞癌（HCC）是世界范围内第五大常见肿瘤,为肿瘤相关死亡的第三大常见原因。由于HCC 早期症状隐匿,大多数患者在确诊时已是中晚期,失去了接受治愈性治疗的机会。目前,HCC的非手术治疗方法很多,包括介入栓塞化疗、消融、放射治疗、化疗和分子靶向治疗等。现有治疗方法的单独或组合应用已被证明能够控制肿瘤生长,延长生存时间,提高生活质量。

关键词: 肝细胞癌, 非手术治疗, 进展

Abstract: Hepatocellular carcinoma （HCC） is the fifth most common cancer and the third most common cause of the tumor-related death worldwide. Because of the absence of clinical symptoms at the early stage,the majority of patients are diagnosed at the intermediate/advanced stage when the options of curative treatments are limited.The approaches for the treatment of primary liver cancer are transcatheter arterial chemoembolization, ablation radiotherapy, chemotherapy,and targeted molecular therapy. These therapeutic methods, either alone or in combination, have been proven to control the tumor growth, prolong survival, and improve quality of life to some extent.

Key words: Hepatocellular carcinoma, Non-surgical management, Progress

侯帅, 樊琳琳(综述), 戴光荣(审校). 非手术治疗原发性肝癌研究进展[J]. 实用肝脏病杂志, 2016, 19(2): 249-252.

Hou Shuai, Dai Guangrong. Progress in non-surgical management of hepatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 249-252.

参考文献

[1] 叶胜龙.关注原发性肝癌多学科治疗.中国医学前沿杂志,2014,6（5）：1-3.
[2] 中华人民共和国卫生部.原发性肝癌诊疗规范（2011 版）摘要.中华肝脏病杂志,2012,20（6）：419-426.
[3] 叶胜龙. 重视原发性肝癌的多学科综合治疗. 中华肝脏病杂志,2013,21（5）：321-323.
[4] Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol,2008,48（1）:20-37.
[5] Bruix J, Sherman M. Practice guidelines committee,American assocition for the hepatocellular carcinama.Hepatolopy,2005,42（5）:1208-1236.
[6] Llovet JM,Real MI,Montana X,et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomized controlled trial .Lancet,2002,359（9319）:1734-1739.
[7] Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival .Hepatology,2003,37（2）:429-442.
[8] Cosgrove DP,Reyes DK,Pawlik TM,et al. Open-lablel single-arm phaseⅡtrial of sorafenib therapy with drug-eluting bead transarterial chemoembolization in patients with unresectable hepatocellular carcinoma:clinical results.Radiology,2015,6（11）:142-148.
[9] Weder W,Kestenholz P,Taverna C,et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in maligant pleural mesothelioma. J Clin Oncol,2004,22（17）: 3451-3457.
[10] Weder W, Stahel RA,Bernhard J,et al. Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol, 2007, 18（7）: 1196-1202.
[11] Lee JH, Chung YH, Kim JA, et al. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.Cancer,2013,119（1）:136-142.
[12] 张明娟,刘佳,向晓星,等.TACE联合索拉非尼治疗晚期肝癌的Meta分析.中华肿瘤防治杂志,2015,22（2）：148-154.
[13] 李慕行,张谞丰,程继文,等.钇-90微球经动脉放疗栓塞治疗不可切除原发性肝癌疗效的Meta分析.中华肝脏外科手术学电子杂志,2014,3（6）：26-30.
[14] Yin XY, Lu MD. Percutaneous ablation for small hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol,2009,3（2）:121-130.
[15] Danila M, Sporea I,Sirli R,et al. Percutaneous ethanol injection therapy in the treatment of hepatocarcinoma-results obtained from a series of 88 cases. J Gastrointestin Liver Dis, 2009,18（3）: 317-322.
[16] Kim SR, Imoto S,Nakajima T,et al. Well differentiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation. Hepatol Int, 2009, 3（2）: 411-415.
[17] Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology,2010,52（2）:762-773.
[18] 孙彪,郑传胜,冯敢生,等.射频消融对比手术切除治疗小肝癌的Meta分析. 世界华人消化杂志,2011,19（31）：3255-3263.
[19] 陈志刚,黄超源,连芳,等.早期肝细胞癌射频消融联合肝动脉化疗栓塞与手术切除疗效Meta分析.中华肿瘤防治杂志,2015,22（1）：59-65.
[20] Yang B,Zou J,Xia J,et al. Risk factors for recurrence of small hepatocellular carcinoma after longterm follow-up of percutaneous radiofrequency ablation. Eur J Radiol,2011,79（2）:196-200.
[21] 汤雨,周晓东.超声介入治疗原发性肝癌的研究进展.第四军医大学学报,2008,29（1）：89-92.
[22] Orsi F,Zhang L,Arnone P,et al. High-intensity focused ultrasound ablation:effective and safe therapy for solid tumors in difficult locations. AJR,2010,195（3）:W245-W252.
[23] 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学分会肝癌学组.肝癌局部消融治疗规范的专家共识.中华肝脏病杂志,2011,19（4）：257-259.
[24] Kerkar S,Carlin AM,Sohn RL,et al. Long-term follow up and prognostic factors for cryotherapy of malignant liver tumors. Surgery,2004,136（4）:770-779.
[25] 张立洁,彭泉,芦东徽,等. 三维适形放疗联合TACE 治疗肝癌并发门静脉癌栓疗效的Meta 分析.实用肝脏病杂志,2015,18（3）：254-257.
[26] 芦东徽,唐隽,周俊平,等.三维适形放射治疗联合经皮肝动脉化疗栓塞不同序贯顺序治疗原发性肝癌伴门静脉癌栓的临床对照.中华肝脏病杂志,2015,23（3）：184-188.
[27] 陈冬,王仁本.原发性肝癌外放疗临床应用现状.中华肿瘤防治杂志,2015,22（1）：76-80.
[28] Swet JH,Pacheco HJ,Ianniti DA,et al. A silica -calcium - phosphate nanocomposite drug delivery system for the treatment of hepatocellular carcinoma:in vivo study. J Biomed Mater Res,2014,102（1）:190-202.
[29] Wang L,Li M,Zhang N. Folate-targeted docetaxel-lipid -based- nanosuspensions for active-targeted cancer therapy. Int J Nanomed,2012,7:3281-3294.
[30] Zhou Q,Sun X,Zeng L,et al. A randomized multicenter phase Ⅱ clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma. Nanomedicine, 2009,5（4）:419-423.
[31] 颜綦先,肖潇,崔红莉,等. 生物微球联合碘油经肝动脉栓塞化疗治疗原发性肝癌临床观察.实用肝脏病杂志,2015,18（3）:245-248.
[32] Chow PK,Tai BC,Tan CK,et al. Asian-pacific hepatocellular carcinoma trialsgroup. high-dose tamoxifen in the treatment of inoperablehepatocellular carcinoma:a multicenter randomized controlledtrial. Hepatology,2002,36（5）:1221-1226.
[33] Bertelli R,Neri F,Tsivian M,et al. Endolymphatic immunotherapy in inoperable hepatocellular carcinoma. Transplant Proc,2008,40（6）:1913-1915.
[34] Barbare JC,Bouche O,Bonnetain F,et al. Treatment of advanced hepatocellular carcinoma with long-acting octreotide:a phase Ⅲ multi-centre,randomised,double blind placebo-controlled study. Eur J Canceer,2009,45（10）:1788-1797.
[35] 张玉怀,罗长江.奥曲肽治疗肝细胞癌有效性和安全性的Meta分析. 临床肝胆病杂志,2015,31（6）：922-926.
[36] 黎元,金海,文国容,等. 泮托拉唑对二乙基亚硝胺联合四氯化碳诱导C57BL/6J小鼠肝癌模型肝细胞增殖的影响.世界华人消化杂志,2015,23（1）：22-29.
[37] 文国容,金海,计蓓,等. 泮托拉唑对人肝癌HepG2 细胞体外迁移和侵袭的影响. 中国新药与临床杂志,2013,32（9）：749-752.
[38] 中华医学会肝病学分会肝癌学组. HBV/HCV相关性肝细胞癌抗病毒治疗专家建议. 中华肝脏病杂志,2013,21（2）：96-100.